Hemab raises USD 55m for treatment of rare bleeding disorders

In less than a year, Danish biotech company Hemab, which builds on technology developed by Novo Nordisk and Genmab, has gone from seed investments to a large capital fund raising round – and now to clinical trials.

Hemab's new CEO, Benny Sørensen | Photo: Hemab / PR

Things have moved quickly at Hemab since the company was founded almost two years ago – and gone even faster since the company secured an introductory seed investment from Novo Holdings in December.

Now, just over six months later, the company has received a series A investment of USD 55m (DKK 350m) from Novo Holdings and two other venture capital funds, Healthcap and RA Capital Management. The company is therefore now able to start clinical trials and put power behind its development of projects within rare bleeding disorders.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs